Leerink Partnrs Cuts Earnings Estimates for Aura Biosciences

Aura Biosciences, Inc. (NASDAQ:AURA) – Research analysts at Leerink Partnrs reduced their Q1 2025 earnings per share (EPS) estimates for Aura Biosciences in a report issued on Tuesday, April 8th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.55) per share for the quarter, down from their prior forecast of ($0.49). The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.66) per share. Leerink Partnrs also issued estimates for Aura Biosciences’ Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.59) EPS, FY2025 earnings at ($2.35) EPS and FY2026 earnings at ($2.72) EPS.

A number of other research firms also recently weighed in on AURA. Citigroup restated an “outperform” rating on shares of Aura Biosciences in a report on Wednesday, March 26th. HC Wainwright set a $25.00 price target on Aura Biosciences in a research report on Tuesday, March 25th. JMP Securities set a $19.00 price target on Aura Biosciences in a research note on Wednesday, March 26th. Finally, Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Aura Biosciences currently has a consensus rating of “Buy” and an average price target of $22.75.

Aura Biosciences Stock Up 6.6 %

NASDAQ AURA opened at $5.30 on Friday. The stock has a market capitalization of $266.19 million, a PE ratio of -3.06 and a beta of 0.43. Aura Biosciences has a 12-month low of $4.84 and a 12-month high of $12.38. The company has a 50 day moving average price of $6.96 and a two-hundred day moving average price of $8.28.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.09).

Insider Transactions at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the sale, the insider now owns 304,692 shares in the company, valued at approximately $2,336,987.64. This trade represents a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 23,045 shares of company stock worth $177,242. Company insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

Large investors have recently bought and sold shares of the stock. Long Focus Capital Management LLC increased its holdings in shares of Aura Biosciences by 123.9% during the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock worth $20,861,000 after purchasing an additional 1,404,228 shares during the period. Levin Capital Strategies L.P. grew its position in Aura Biosciences by 169.1% during the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock worth $10,255,000 after buying an additional 783,984 shares in the last quarter. B Group Inc. bought a new position in Aura Biosciences during the fourth quarter valued at about $3,885,000. Franklin Resources Inc. raised its holdings in Aura Biosciences by 14.8% in the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after acquiring an additional 215,597 shares in the last quarter. Finally, Ensign Peak Advisors Inc lifted its position in shares of Aura Biosciences by 43.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock worth $3,212,000 after acquiring an additional 118,000 shares during the period. 96.75% of the stock is currently owned by institutional investors and hedge funds.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.